Current signal or inherited risk?

Galleri vs Whole Genome Sequencing: Two Questions, Two Tests

Galleri looks for a cancer signal in blood now. A genome reads inherited DNA once. Here is what each can—and cannot—tell you.

Compare the tests
HLI editorial team

Evidence checked by the editorial team. A named medical reviewer and genetic counselor were not supplied, so none is represented in the page or schema.

The answer first

Galleri® (powered by GRAIL) and whole genome sequencing answer different questions. Galleri looks for a cancer signal in DNA that cancer cells shed into your blood now, and GRAIL says it does not predict future genetic risk for cancer. Whole genome sequencing reads the DNA you inherited, once, and it does not detect a cancer that is already present.

Galleri is under FDA review. An advisory panel voted 7–2, with one abstention, on benefit versus risk on September 23, 2026; the vote is non-binding and no FDA decision has been announced. See where the FDA review stands.

Seller disclosure: Human Longevity sells both the Galleri test through Human Longevity and whole genome sequencing. We have a commercial interest in each, and this page says what each cannot do.

The word “sequencing” causes confusion

Is Galleri a Whole Genome Sequencing Test?

No. Galleri sequences cell-free DNA fragments from a blood draw and reads their methylation patterns at hundreds of thousands of sites using a targeted design. It does not sequence your whole genome or report inherited variants. Whole genome sequencing reads nearly all of an individual's inherited DNA.

Three meanings of sequencing
Use of “sequencing”DNA readSample and timingWhat it means here
Germline whole genome sequencingInherited DNA across nearly the whole genomeSaliva or blood; generally onceLooks for inherited variation. It does not detect current cancer.
GalleriTargeted cell-free DNA methylation at hundreds of thousands of sitesBlood; intended to be repeatedLooks for a cancer-associated signal and predicts its likely origin.
Research whole-genome cfDNA assaysWhole-genome methylation patterns in cell-free DNAResearch blood samplesJeong et al. reported a retrospective 2026 study of 1,415 samples; it was not a Galleri study and authors declared company interests.

The same phrase is used for three distinct methods. Galleri's targeted methylation design is described by Klein et al. in Annals of Oncology (2021).

One is repeated; one is read once

Galleri and Whole Genome Sequencing Side by Side

Galleri asks whether a cancer signal is in your blood now. Whole genome sequencing asks what you inherited. A normal result from either test does not rule out cancer.

Galleri and whole genome sequencing compared; facts last checked October 5, 2026
QuestionGalleri® (GRAIL), sold by HLIWhole genome sequencing (HLI)
Question it answersIs there a cancer-associated signal in blood now, and where might it come from?What inherited variants do you carry that may bear on future risk?
DNA readTargeted cell-free DNA methylationWhole genome; about 30× average coverage (HLI claim, not a guarantee at every position)
Sample and timingBlood draw; point-in-time and intended for annual useAt-home saliva kit; generally once because inherited DNA does not change
A “positive” means“Cancer Signal Detected”; diagnostic workup is neededA variant linked to higher risk; it may change screening, not whether cancer is present
A “negative” means“No Cancer Signal Detected” does not rule cancer outNo known harmful variant found in the assessed data; it does not mean zero risk
Cannot doDetect all cancers, predict genetic risk or diagnose cancerDetect existing cancer, replace screening or resolve every variant of uncertain significance
Regulatory statusLaboratory-developed test; under FDA review, with no decision announcedHLI states its sequencing laboratory is CLIA-certified and makes no FDA approval or clearance claim for the service
Price at HLI$798; not covered by Medicare or most insurance$599 one time; insurance and HSA/FSA treatment are not stated here because they remain unconfirmed
Who it is forAdults 50 or older or at elevated risk; not people who are pregnant, 21 or younger, or in active cancer treatmentAdults seeking inherited-risk information; specific age and eligibility rules should be confirmed before ordering

Sources: GRAIL patient and HCP FAQs, NCI genetic-testing guidance and HLI's whole genome sequencing page. Neither test replaces guideline screening.

Current signal is not inherited risk

Is Galleri a Genetic Test?

Not in the sense most people mean. GRAIL says Galleri identifies DNA shed by cancer cells and “does not predict future genetic risk for cancer.” Germline genetic tests look for inherited changes that can raise future risk and are usually done once.

GRAIL states that about 90–95% of cancers are not hereditary. NCI similarly says up to 10% of all cancers may be caused by inherited genetic changes. Galleri is therefore not a way to learn whether you carry a cancer-predisposition variant.

Galleri is designed to look for a shared cancer signal associated with more than 50 cancer types. That does not mean it detects every cancer, and a No Cancer Signal Detected result does not rule cancer out. Review the Galleri test through Human Longevity.

A predisposition can change screening

What Can Whole Genome Sequencing Tell You About Cancer Risk?

Whole genome sequencing can identify inherited variants associated with cancer predisposition, including changes in BRCA1 and BRCA2. NCI reports that more than 60% of women with an inherited harmful BRCA1 or BRCA2 change develop breast cancer in their lifetime, compared with about 13% of women overall. A finding can change screening; it does not show whether cancer is present now.

NCI estimates ovarian cancer risk at 39–58% with a harmful BRCA1 change and 13–29% with a harmful BRCA2 change, compared with about 1.1% in the general population. Options can include earlier screening, MRI in addition to mammography, medication or risk-reducing surgery; each has trade-offs. Read about BRCA1 and BRCA2 testing and Lynch syndrome and inherited colorectal cancer risk.

In the 2018 Geisinger MyCode exome study of 50,726 research volunteers, 267 (0.5%) carried a pathogenic BRCA1/2 variant. Eighty-two percent had no prior clinical testing; among 89 carriers with full history data and no prior testing, 44 did not meet published testing criteria. The study involved one health system, exome—not whole genome—sequencing, and BRCA1/2 only.

How HLI describes its report

HLI says its genome report offers a cancer risk assessment covering BRCA1 and BRCA2 among others. That is HLI's product claim, not a guarantee that every gene or variant type is resolved. Findings that may affect care need clinical confirmation and genetic counseling.

A clear genome is not an all-clear

What Whole Genome Sequencing Cannot Tell You

Whole genome sequencing does not detect a cancer that is already growing. NCI notes that a negative genetic test can be an “uninformative negative” in someone with a strong family history because the family may carry a change that current testing cannot identify. Most cancers are not caused by one inherited variant.

  • Variants of uncertain significance are real findings whose health meaning is not yet established.
  • HLI notes that polygenic-risk models were built largely with people of European ancestry and can be less accurate for people from other backgrounds.
  • NCI cautions that consumer-directed testing can assess more genes than are clinically necessary; counseling helps match the test to the family history.
  • The 2019 USPSTF BRCA recommendation supports risk assessment, counseling and testing for women with qualifying history or ancestry (Grade B), and recommends against routine assessment for women without it (Grade D). That guidance concerns clinical BRCA testing—not consumer genome sequencing.
  • A low genetic risk is never a reason to skip screening your clinician recommends.

Complementary does not mean proven together

Why Do People Pair Them, and What Does the Evidence Show?

The case for pairing is that whole genome sequencing asks what you are predisposed to, while Galleri asks whether a cancer signal is present now. No study has tested the pair—or any package—as a combined protocol. Pairing is a way to get two different answers, not a guideline-recommended strategy.

Why some consider both

The argument is indirect

Eric Topol wrote in October 2025 that multi-cancer tests might first be considered in people selected as high risk by factors such as family history, polygenic score or whole genome sequencing: “in a bona fide high-risk individual that may deserve consideration.”

A Weill Cornell and MD Anderson feasibility study in BRCA1/2 carriers planning risk-reducing surgery, NCT07764744, was first submitted August 10, 2026. It was not yet recruiting and planned about 70 participants.

What remains unknown

No combined-outcome evidence

PATHFINDER 2 enrolled 35,878 adults age 50 or older without a genomic risk filter. GRAIL reported 69.8% sensitivity for 12 pre-specified cancers, 39.3% across all cancers, 99.6% specificity and 60.3% positive predictive value on May 31, 2026.

NHS-Galleri did not meet its primary endpoint, although its 12-cancer analysis reported fewer stage IV and more stage I–III diagnoses. No guideline includes Galleri, and a genome result has not been shown to improve what Galleri finds or what happens next.

The FDA advisory panel votes were non-binding. Review the current MCED evidence and where the FDA review stands.

Start with the question and the clinical context

Who Should Consider Galleri, Genome Sequencing, Both or Neither?

Galleri is labelled for adults 50 and older or at elevated risk and is meant to be used in addition to recommended screening. Whole genome sequencing suits adults who want inherited-risk information. People with symptoms should see a clinician before either test. Read more about who should get the Galleri test.

Decision guide by personal situation
SituationGalleri labelGenome sequencingWhat to do first
50 or older, no family historyWithin labelled age/risk use; supplemental onlyOptional information, not a guideline-backed stepMake sure guideline screening is current
Family history of breast, ovarian, colorectal or pancreatic cancerMay fit elevated-risk useMay provide inherited-risk informationRisk assessment and genetic counseling first
Known BRCA or Lynch carrierNot proven as a carrier-specific protocolA repeat consumer genome is not the first needGenetic counselor and clinician-directed enhanced screening
Under 50 with no known riskNot the usual intended populationOptional, with age eligibility confirmed before orderingFollow age-appropriate guideline screening
SymptomsNeitherNeitherSee a clinician for diagnostic evaluation
Pregnant or in active cancer treatmentNot recommended by GRAILNot a substitute for obstetric or oncology careSpeak with the treating clinician

Two separate prices

Cost and What Is Included

Through Human Longevity, Galleri costs $798 and whole genome sequencing costs $599 one time—a total of $1,397 if purchased separately. Galleri is not covered by Medicare or most insurance. No combined package is represented here because its existence, name and price have not been confirmed.

$798

Galleri

Human Longevity's existing Galleri ordering experience describes physician eligibility review, the order, a scheduled blood draw and results review. The price does not include diagnostic follow-up after a Cancer Signal Detected result. See Galleri cost and coverage.

$599

Whole genome sequencing

HLI says this includes sequencing, the report, lifetime access to your data and one year of the HLI app. Lifetime data access and the app term are separate. Insurance, HSA/FSA treatment and genetic-counseling inclusion are not confirmed here.

The Nancy Gardner Sewell Medicare MCED Screening Coverage Act, signed February 3, 2026, allows possible Medicare coverage of FDA-approved MCED tests from 2028 at the earliest, subject to phased age limits and a CMS decision. Galleri would first need FDA approval.

Both results can start another process

What Happens After a Result?

A Galleri Cancer Signal Detected result needs diagnostic testing, often imaging guided by the predicted signal origin, and that workup is not included in the Galleri price. A genome finding such as a BRCA variant is a starting point that needs clinical confirmation and review with a genetic counselor.

Galleri result

Signal detected—or not

In PATHFINDER 2, diagnostic resolution took a median of 48 days, and 0.6% of participants had an invasive procedure. A No Cancer Signal Detected result does not rule out cancer. Review what a Cancer Signal Detected result means.

Genome result

Risk information needs context

A potentially high-risk inherited finding can affect screening and blood relatives. It should be confirmed in a clinical-grade test and interpreted with a clinician or genetic counselor before care changes.

Clear answers

Frequently Asked Questions

01

Is Galleri a genetic test?

No, not in the inherited-risk sense. GRAIL says Galleri does not predict future genetic risk for cancer. It looks for cancer-associated cell-free DNA methylation patterns in blood.

Read the full answer
02

Does Galleri use whole genome sequencing?

No. Galleri uses targeted methylation sequencing of cell-free DNA. It does not sequence your whole genome or report inherited variants.

See how the methods differ
03

Can whole genome sequencing detect cancer?

No. Whole genome sequencing reads inherited DNA and cannot show whether a cancer is present now. A clear genome result is not an all-clear.

04

Should I get both Galleri and whole genome sequencing?

Only if you want both kinds of information. No study has tested the pair as a combined protocol, and neither test replaces guideline screening.

Use the decision guide
05

Is the Galleri cancer blood test worth it?

The evidence is mixed. PATHFINDER 2 reported prospective performance in 35,878 adults, while NHS-Galleri did not meet its primary endpoint. No guideline includes Galleri, and it remains under FDA review.

Review the evidence in context
06

What is the newest blood test that can detect cancer?

Galleri was the first multi-cancer early detection test to reach an FDA advisory panel, on September 23, 2026. Other tests exist, but their intended uses and evidence differ.

Learn about multi-cancer early detection tests explained and Galleri vs Shield.

07

Does insurance cover the Galleri test?

Galleri is not covered by Medicare or most insurance today. It costs $798 through Human Longevity.

See cost and coverage details
08

What is the best genetic testing for cancer?

For people who meet testing criteria, clinical multigene panel testing with a genetic counselor is the standard route. Whole genome sequencing is a broader read; ask a clinician which approach fits your history.

The broader read has a specific role

Where Whole Genome Sequencing Fits, and Where It Does Not

Whole genome sequencing reads your inherited DNA once, which Galleri does not do, and it cannot detect a cancer already present, which Galleri attempts to do from a blood signal. For someone with a family history that meets testing criteria, a clinical panel ordered with a genetic counselor is the standard route; a genome is a broader read, not a substitute.

A genome can still be useful because it answers a question Galleri cannot: what you may be predisposed to across more than cancer. HLI describes a cancer risk assessment covering BRCA1 and BRCA2 among others, but has not publicly confirmed every gene and variant type covered for this page.

A clear result is not an all-clear. It does not remove the need for mammography, colonoscopy or other recommended screening. If you want both kinds of information, buying both tests gets two separate answers—not a combined protocol proven to improve outcomes.

See what the $599 genome service includes

Sources and Evidence Notes

Primary government, trial-registry, peer-reviewed and manufacturer sources support the distinctions and dated status claims on this page. Company sources are identified as such.

  1. Galleri — test purpose and important safety information
  2. GRAIL HCP FAQ — hereditary testing distinction
  3. Klein et al., Annals of Oncology (2021)
  4. GRAIL — PATHFINDER 2 full-results release, May 31, 2026
  5. ASCO — NHS-Galleri patient summary, 2026
  6. NCI — The Genetics of Cancer
  7. NCI — BRCA Gene Changes: Cancer Risk and Genetic Testing
  8. NCI — Genetic Testing for Inherited Cancer Risk
  9. USPSTF — BRCA-related cancer recommendation (2019)
  10. Manickam et al., Geisinger MyCode study (2018)
  11. ClinicalTrials.gov — NCT07764744
  12. Eric Topol, Ground Truths, October 20, 2025
  13. Jeong et al., Experimental & Molecular Medicine, April 21, 2026
  14. Human Longevity — Whole Genome Sequencing
  15. FDA — September 2026 advisory committee materials
  16. Congress.gov — H.R.842